Baudax Bio: Q2 Earnings Insights

 

Shares of Baudax Bio BXRX rose 0.1% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 87.79% year over year to ($0.21), which missed the estimate of ($0.20).

Revenue of $201,000 declined by 42.41% year over year, which missed the estimate of $470,000.

Guidance

Baudax Bio hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Aug 05, 2021

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/uncpck7j

Price Action

Company's 52-week high was at $3.94

Company's 52-week low was at $0.57

Price action over last quarter: down 27.59%

Company Overview

Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs, and a related proprietary chemical reversal agent and Dex-IN.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!